ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PAR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Paradigm Biopharmaceuticals alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Paradigm Biopharmaceuticals Stock (ASX:PAR)Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) PAR Stock News HeadlinesMarch 27, 2024 | msn.comParadigm Signs ‘Red, White & Royal Blue’ Breakout Taylor Zakhar PerezMarch 20, 2024 | msn.comLit Agents Alysia Thomas, Kelsey Roberts Exit ParadigmMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 19, 2024 | uk.movies.yahoo.comParadigm Hires Verve Alums Bill Weinstein, Devon Schiff As Lit AgentsMarch 19, 2024 | msn.comBill Weinstein Joins Paradigm Talent Agency Following Verve ExitMarch 19, 2024 | msn.comBill Weinstein & Paradigm At The Altar? – The DishMarch 18, 2024 | msn.comOcugen's Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the HorizonMarch 13, 2024 | finance.yahoo.comShift Paradigm acquires design and technology consultancy Principle StudiosMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 11, 2024 | msn.comMonad Labs in talks to raise more than $200 million round led by Paradigm, valuing the Jump Crypto–linked startup at $3 billionFebruary 29, 2024 | tmcnet.comParadigm by Puloli™ Announces Customers in Eagle FordFebruary 27, 2024 | msn.comJaime King Signs With ParadigmFebruary 27, 2024 | msn.comWhat’s in store for 2024: Paradigm BiopharmaceuticalsFebruary 23, 2024 | tmcnet.comGlobal Disinfection Robots Market Report 2024: Analysis of Funding and Investments for Developing Disinfection RobotsFebruary 22, 2024 | yahoo.comParadigm Hires Kyle Jensen and Jamie Kaye-Phillips, Promotes Matthew Nutty, Taps Brian Neal for Napoli Management GroupFebruary 20, 2024 | msn.comASX stocks striving to inject youthfulness into an aging world populationFebruary 14, 2024 | bloomberg.comParadigm’s Famed ‘White-Hat’ Hacker Unites Peers Against Crypto AttacksFebruary 11, 2024 | finance.yahoo.comParadigm Biopharmaceuticals Limited (ASX:PAR) Is Expected To Breakeven In The Near FutureFebruary 8, 2024 | morningstar.comParadigm Biopharmaceuticals Ltd PARFebruary 7, 2024 | finance.yahoo.comProkarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical TrialFebruary 6, 2024 | stockhouse.comRenovoRx CEO Issues Letter to ShareholdersFebruary 6, 2024 | fool.com.auHere's a 33c ASX stock that could have the potential to reach $1+February 5, 2024 | finance.yahoo.comNodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical OfficerJanuary 13, 2024 | msn.comSingle-use technologies in the biopharmaceutical industryJanuary 9, 2024 | markets.businessinsider.comInside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB TrialJanuary 8, 2024 | finance.yahoo.comCRISPR Therapeutics Highlights Strategic Priorities and 2024 OutlookDecember 27, 2023 | msn.comASX biotechs with big catalysts in 2024: Part 2See More Headlines Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PAR CUSIPN/A CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,031Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.42% Return on Assets-72.47% Debt Debt-to-Equity Ratio0.86 Current Ratio3.83 Quick Ratio5.93 Sales & Book Value Annual Sales$79,224.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares351,200,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.92 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Paul John Rennie BSc (Age 65)Grad Dip, MBM, MSTC, Founder, MD & Executive Chairman Comp: $1.75MDr. Donna L. Skerrett M.D. (Age 67)MS, Chief Medical Officer and Executive Director Comp: $1.26MMs. Abby Macnish Niven B.Com.B.Sc., C.F.A., Interim Company Secretary & Interim CFODr. Ravi KrishnanChief Scientific OfficerMr. Simon WhiteDirector of Investor RelationsDr. Michael ImperialeGlobal Head of Drug Safety & MPSMs. Beverley HuttmannCommercial HeadMs. Michelle CoffeyGlobal Head of Regulatory AffairsDr. Mukesh AhujaGlobal Clinical Head of OAMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPaul RennieSold 349,500 sharesTotal: $136,305.00 ($0.39/share)Helen FisherBought 10,204 shares on 5/18/2023Total: $10,020.33 ($0.98/share)Paul RennieBought 73,851 shares on 5/12/2023Total: $75,992.68 ($1.03/share) PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), a2 Milk (A2M) and 8common (8CO). This page (ASX:PAR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesThe 3rd Revolution in WarfareWeiss RatingsFed launches fourth dollar overhaulStansberry ResearchAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.